Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : eDrugstores: Drugstore.com, PlanetRx and Soma -- Ignore unavailable to you. Want to Upgrade?

To: Jim Davison who wrote (229)	11/11/1999 1:42:00 PM
From: Tom D	Read Replies (1) \| Respond to of 254

PLRX beats expectations. After the close of trading, PlanetRx.com (PLRX: news, msgs) posted a narrower-than-expected pro forma net loss of $22.9 million, or 83 cents a share, in the third quarter. Analysts surveyed by First Call expected a loss of 97 cents. Revenue rose 308 percent to $3.1 million from $755,000 from the previous quarter. The online drugstore said membership increased to 310,000 in the quarter, an sequential increase of 230,000. The San Francisco-based company raised approximately $102 million in its stock debut last month. Shares closed up 3/8 at 18 3/8. I chose DSCM over PLRX because 1) PLRX does not have a bricks and mortar drugstore in its system. The way that DSCM gets reimbursement for 85 to 90% of prescriptions is through its relationship with Rite Aid. 2) DSCM appears to be getting their EDI into place faster than PLRX. In fact, it looks like DSCM is much more involved than any other eDrugstore in creating the NCPDP standards for ePrescribing. And I agree that Rite Aid is a drag on DSCM, but I don't know how much. I think this thread will take off in parallel with the rise of eDrugstores. Until then, I am content to trade emails with Firenze (who is one very smart dude) and anybody else who is interested. Tom

To: Jim Davison who wrote (229)	11/16/1999 11:30:00 PM
From: Firenze	Read Replies (1) \| Respond to of 254

Jim, I am not so sure about the PLRX at this point, as the relationship with ESRX seems to be one-sided... but good luck in any case. As for RAD, I have actually bought (@$7) it on this terrible news of the trouble with accounting practices. I personally would be shocked if it does not reach $10-$15 in a year. Regardless of the eDrugstores, they will continue to have significant revenue growth for the long-term. I am not sure if RAD has had a drag on the eDrugstores at this time, because others in the sector are also down (WAG, CVS), so I suppose the whole sector is weighing down PLRX and DSCM. IMO eDrugstores are not flying because of the many issues, TOM D and I have been sharing, namely reimbursement from the big players (ESRX, MMRX/UNH and AET/CI/WLP/Pacificare). Firenze